Generic Name and Formulations:
Pramoxine HCl 1%, hydrocortisone acetate 1%; aerosol foam.
Indications for PROCTOFOAM-HC:
Steroid-responsive anogenital dermatoses.
Apply 3–4 times daily.
Apply least amount compatible with therapeutic regimen.
Tuberculosis. Diverticulitis. Treat infection if present. Significant systemic absorption may occur. Discontinue if no improvement in 2–3 weeks. Children. Vaccinations. Pregnancy (Cat.C). Nursing mothers.
Anesthetic + steroid.
Adrenal suppression, dermal and epidermal atrophy, poor wound healing, local irritation: folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, macerations, secondary infections, striae, miliaria.
Aerosol—10g (w. applicator)
Neurology Advisor Articles
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- Loss of Function Variants in LRRK1 and LRRK2 Not Linked to Parkinson Disease
- Smoking Promotes Disease Progression in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- ZTlido Patch for Post-Shingles Pain Launching Soon
- Managing Complications of Intrathecal Baclofen Therapy
- Deep Brain Stimulation Reduces Tremor Symptoms in Parkinson Disease
- FDA Issues Statement Addressing Safety Concerns Associated With Nuplazid
- Prevalence of Autoimmune Encephalitis in Herpes Simplex Encephalitis Explored